



Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation

Guest Editor:

Dr. Silvia Vidal

Department of Immunology,
Institut de Recerca, Hospital de
la Santa Creu i Sant Pau,
Barcelona, Spain

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

There is a growing interest in finding accurate non-invasive biomarkers for the identification of patients who might benefit from biologic therapy. Although this therapy has dramatically changed clinical practice, its benefits are curbed by the heterogeneous response of patients. It is therefore of utmost importance to find markers that predict the patient response to biologic therapy. To achieve this aspect of personalized medicine, one major step forward may be finding non-invasive biomarkers in human fluids (blood, saliva, urine, pleural fluid, tears, etc.).

In this Special Issue, experts in the field of cancer and inflammation will describe the most recent approaches (liquid biopsy, high throughput omics, extracellular vesicles, functional assays, etc.) to find non-invasive biomarkers of response to biologic therapy. This will include research articles using different sources of samples to apply these approaches.

- immunotherapy
- personalized medicine
- prognosis markers





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)